Mass Spectrometry Detection and Imaging of a Non-Covalent Protein-Drug Complex in Tissue from Orally Dosed Rats.
Eva Illes-TothOliver J HaleJames W HughesNicole StrittmatterJonathan RoseBen ClaytonRebecca SargeantStewart JonesAndreas DannhornRichard J A GoodwinHelen J CooperPublished in: Angewandte Chemie (Weinheim an der Bergstrasse, Germany) (2022)
Here, we demonstrate detection by mass spectrometry of an intact protein-drug complex directly from liver tissue from rats that had been orally dosed with the drug. The protein-drug complex comprised fatty acid binding protein 1, FABP1, non-covalently bound to the small molecule therapeutic bezafibrate. Moreover, we demonstrate spatial mapping of the [FABP1+bezafibrate] complex across a thin section of liver by targeted mass spectrometry imaging. This work is the first demonstration of in situ mass spectrometry analysis of a non-covalent protein-drug complex formed in vivo and has implications for early stage drug discovery by providing a route to target-drug characterization directly from the physiological environment.
Keyphrases
- mass spectrometry
- binding protein
- high resolution
- small molecule
- early stage
- liquid chromatography
- protein protein
- adverse drug
- high performance liquid chromatography
- gas chromatography
- capillary electrophoresis
- squamous cell carcinoma
- cancer therapy
- quantum dots
- drug delivery
- label free
- electronic health record
- simultaneous determination